Ocugen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
OCGN Nasdaq 8731 https://ocugen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocugen Inc

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets - Apr 12th, 2024 11:30 am
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Apr 10th, 2024 11:02 am
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study - Apr 8th, 2024 4:13 pm
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication - Apr 8th, 2024 10:30 am
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy - Apr 5th, 2024 11:02 am
Q4 2023 Ocugen Inc Earnings Call - Apr 3rd, 2024 2:50 am
Ocugen (OCGN) Q4 2023 Earnings Call Transcript - Apr 2nd, 2024 11:00 pm
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 - Apr 2nd, 2024 12:00 pm
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease - Apr 1st, 2024 10:08 pm
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 - Apr 1st, 2024 9:43 pm
3 Stocks Under $5 Ready to Outpace the Market - Mar 25th, 2024 11:32 am
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer - Mar 18th, 2024 10:30 am
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 - Mar 13th, 2024 12:00 pm
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street - Mar 7th, 2024 10:28 am
Ocugen to Present at Investing in Cures Summit - Mar 6th, 2024 12:30 pm
Ocugen Clinical Showcase Webcast Now Available - Feb 28th, 2024 1:00 pm
Meme Stock Meltdowns: 3 Names to Sell Before They Crash - Feb 26th, 2024 9:34 pm
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit - Feb 26th, 2024 1:30 pm
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST - Feb 22nd, 2024 9:05 pm
Ocugen to Present at 2024 BIO CEO & Investor Conference - Feb 21st, 2024 9:05 pm